

Cyclacel Pharmaceuticals, Inc.  
Form 8-K  
November 27, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 26, 2007**

**CYCLACEL PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-50626**

(Commission File Number) **91-1707622**  
(IRS Employer Identification No.) **200 Connell Drive**  
**Suite 1500**  
**Berkeley Heights, NJ 07922**  
(Address of principal executive offices and zip code)

**(908) 517-7330**

(Registrant's telephone number, including area code)

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



**Item 8.01 Other Events.**

Attached as Exhibit 99.1 is a copy of a press release issued by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the Company), dated November 26, 2007, providing an overview of recent advances in its clinical development stage programs and announcing its 2008 key business objectives for such programs.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Number

Description

99.1

Press release, dated November 26, 2007

---



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By:

/s/ Paul McBarron

Name:

Paul McBarron

Title:

Executive Vice President Finance and  
Chief Operating Officer

Date: November 27, 2007







**EXHIBIT INDEX**

**Exhibit**

**No**

**Description**

**99.1**

Press Release, dated November 26, 2007

---